Related Experiment Video
Updated: Aug 9, 2026

Using Reverse Genetics to Manipulate the NSs Gene of the Rift Valley Fever Virus MP-12 Strain to Improve Vaccine Safety and Efficacy
Published on: November 1, 2011
Development and characterization of the genotype F attenuated mumps candidate strains
Hongtao Liu1,2,3, Na Liu1, Yueqiu Sun1
1Vaccines R&D Department, Changchun Keygen Biological Products Co., Ltd., Changchun, Jilin, China.
Background:
Mumps is an acute infectious disease caused by the mumps virus (MuV), primarily affecting the parotid glands, though it can also lead to systemic infections, including the nervous system. In China, the predominant circulating MuV genotype is F, while the vaccine strain (S79 or WM84) belongs to genotype A, raising concerns about immunization effectiveness.
Methods:
A genotype F MuV strain was isolated from throat swabs of six suspected mumps patients. Through cell adaptation passage and plaque purification, two candidate vaccine strains QBB-2BS-3.2 and QBB-2BS-9.3 were prepared. Their immunogenicity was assessed by neutralizing antibody and cell-mediated immune responses in immunized mice. Additionally, neurotoxicity was evaluated in neonatal Lewis rats.
Results:
Both QBB-2BS-3.2 and QBB-2BS-9.3 elicited strong neutralizing antibody responses and robust cell-mediated immune responses in mice. Notably, neurotoxicity testing revealed minimal neurotoxicity in QBB-2BS-3.2 and QBB-2BS-9.3 strains, comparable to the S79 vaccine strain.
Conclusions:
This study successfully developed two attenuated genotype F MuV candidate strains with favorable immunogenicity and safety profiles, laying a critical foundation for the development of genotype F mumps live attenuated vaccines.
Insights
Two new mumps virus (MuV) genotype F vaccine candidates were developed. These strains show strong immunogenicity and low neurotoxicity, addressing concerns about current vaccine effectiveness against circulating MuV strains.
Area of Science:
- Virology
- Vaccinology
- Immunology
Background:
- Mumps virus (MuV) causes acute infections, potentially affecting the nervous system.
- The prevalent MuV genotype F in China differs from genotype A vaccine strains, impacting immunization effectiveness.
Purpose of the Study:
- To develop and evaluate novel mumps virus genotype F candidate vaccines.
- To assess the immunogenicity and safety of these new strains.
Main Methods:
- Isolation of a genotype F MuV strain from patients.
- Preparation of two candidate vaccine strains (QBB-2BS-3.2 and QBB-2BS-9.3) through cell adaptation and plaque purification.
- Evaluation of immunogenicity (neutralizing antibodies, cell-mediated immunity) in mice and neurotoxicity in rats.
Main Results:
- Both candidate strains induced significant neutralizing antibody and cell-mediated immune responses in mice.
- Neurotoxicity assessments showed minimal adverse effects, comparable to the existing S79 vaccine strain.
Conclusions:
- Two attenuated genotype F MuV candidate strains were successfully created.
- These strains demonstrate promising immunogenicity and safety, supporting the development of genotype F mumps live attenuated vaccines.
More Related Videos
12:42Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
12:53Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development
Published on: March 16, 2022
Related Concept Videos
Differential Staining Technique
Conjugation
Development of Antibiotic Resistance
Probiotics
Microbiota Modulation by Antibiotics
Clinical Significance of Antibiotic Resistance